Home » Topics » Musculoskeletal, BioWorld Science

Musculoskeletal, BioWorld Science
RSS

Cypress Bioscience to collaborate with Fresenius; FDA requests more information for Prosorba Column

Jan. 27, 1999

British Biotech continues search for MMP inhibitors

Jan. 25, 1999

Searle's celecoxib: the first COX-2 inhibitor reaches the market

Jan. 25, 1999

Celebrex approved in first market outside U.S.

Jan. 22, 1999

Snow Brand reports new developments concerning cevimeline

Jan. 22, 1999

Chugai presents new COX-2 inhibitor series

Jan. 22, 1999

Medarex and Centeon begin phase II study of MDX-33 as ITP treatment

Jan. 14, 1999

Medeva acquires license for scleroderma Rx from Connetics

Jan. 13, 1999

Priority review status granted for Merck & Co.'s COX-2 inhibitor

Jan. 13, 1999

Max Planck reports cysteine-containing compounds as MMP inhibitors

Jan. 12, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Kymera’s IRF5 degrader shows potential in IBD treatment
BioWorld Science
At the recently concluded Digestive Disease Week, researchers from Kymera Therapeutics Inc. presented preclinical efficacy data on KT-579, a selective oral IRF5...
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...